Novo Nordisk (NOVOB.DK) shares are losing 20% after the pharmaceutical giant, known for its obesity drugs Ozempic and Wegova, released disappointing clinical trial data for its experimental obesity drug CagriSema. Patients treated with Novo's next-generation weight-loss drug CagriSema lost an average of 22.7% of their weight after 68 weeks, falling short of the 25% goal the drugmaker expected. About 40% of patients lost 25% or more of their body weight.
The company's shares are trading at their lowest since August 2023. Source: xStation
āļāļ§āļēāļĄāđāļŠāļĩāđāļĒāļāļāļēāļāļāļ§āļēāļĄāļĨāđāļēāļāđāļēāđāļĢāļīāđāļĄāļāļāļāļąāļ âāđāļĢāļ·āđāļāļāđāļĨāđāļēāļĄāļđāļĨāļāđāļēāļŦāļļāđāļâ āļāļāļ Nvidia āđāļĨāđāļ§āļŦāļĢāļ·āļāļĒāļąāļ?
āļŠāļĢāļļāļāļ āļēāļ§āļ°āļāļĨāļēāļāđāļāđāļē (06.07.2026)
āļāđāļēāļ§āđāļāđāļāļ§āļąāļāļāļĩāđ 6 āļ.āļ.
3 āļāļĨāļēāļāļāđāļēāļāļąāļāļāļēāđāļāļŠāļąāļāļāļēāļŦāđ: OIL, US100 āđāļĨāļ° NZDUSD
